Oramed Pharmaceuticals

Company Overview

Snapshot

Founded in March 2006 by Nadav Kidron and Miriam Kidron, Oramed Pharmaceuticals operates with 11–50 employees. The company has raised a total of $149.13 million across 10 funding rounds from 3 investors. In October 2025, Oramed released a letter to shareholders highlighting developments in its oral insulin program, significant investment appreciation, and upcoming growth initiatives, including the launch of a new U.S. trial.

Business overview

Oramed Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing oral delivery solutions for drugs currently administered via injection. Its proprietary platform technology enables the oral administration of protein-based therapies. The company's flagship product is an oral insulin capsule, ORMD-0801, which is in advanced Phase 3 clinical trials for the treatment of type 2 diabetes under the US FDA and European EMA. Oramed operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drug Delivery, serving the pharmaceutical industry across markets including Asia, the United States, and Europe.

Strategic signal

In October 2024, Oramed Pharmaceuticals announced a restructuring of its debt with Scilex Holding Company. This strategic financial maneuver indicates Oramed's active management of its investment portfolio and financial obligations, which is a key signal for investors regarding the company's operational stability and its ability to navigate complex financial landscapes while continuing its core pharmaceutical development.

Company Intelligence Q&A

What is Oramed Pharmaceuticals' core technology?

Oramed Pharmaceuticals has developed a proprietary platform technology that allows for the oral delivery of drugs currently administered only via injection, aiming to transform injectable therapies into oral treatments.

What is the status of Oramed's oral insulin program?

Oramed's oral insulin, ORMD-0801, is in advanced Phase 3 clinical trials under the US FDA and European EMA for the treatment of type 2 diabetes. In October 2025, Oramed announced it is advancing its oral insulin program independently and launching a new U.S. trial.

When did Oramed Pharmaceuticals become a public company?

Oramed Pharmaceuticals went public on NASDAQ in April 2006 and on TASE in July 2017.

What was a significant financial transaction Oramed Pharmaceuticals engaged in recently?

In September 2023, Oramed announced a $101,875,000 short-term senior secured note transaction with Scilex Holding Company.

Has Oramed Pharmaceuticals engaged in any strategic partnerships for commercialization?

In November 2022, Oramed signed a definitive deal with Medicox to commercialize oral insulin in South Korea.